Goldman Sachs initiates coverage on Talecris Biotherapeutics (Nasdaq: TLCR) with a Neutral rating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE